Examples of using Agonists in English and their translations into Croatian
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
The concomitant use of other systemic alpha adrenergic receptor agonists may potentiate the undesirable effects of this class of medicinal products in patients.
called‘carbonic anhydrase inhibitors' and brimonidine tartrate belongs to a group of medicines called‘alpha-2 adrenergic receptor agonists.
I would also replace commercial GABA agonists(soothing medicines)
dopaminergic agonists, and anticholinergics may be enhanced by concomitant treatment with NMDA-antagonists such as memantine.
Patients currently dependent on chronic opioids(see sections 4.4 and 4.5) or opiate agonists(e.g., methadone),
As a sportsboy, you know the basics of physiology, and I do not have to explain what the receptors and their agonists are.
Drugs that have destroyed many people around me are GABA A receptor agonists known as"sleeping pills".
and other agonists to induce platelet aggregation.
Relvar Ellipta should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long- acting beta2-adrenergic agonists. .
belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain.
Do not use Saxenda in combination with other medicines that contain GLP-1 receptor agonists(such as exenatide or lixisenatide).
Olanzapine may antagonise the effects of direct and indirect dopamine agonists see section 6.2.
acute renal failure have been reported in clinical trials with GLP-1 receptor agonists including liraglutide,
belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain.
in patients who are unusually responsive to beta2-adrenergic agonists.
than recommended doses of conventional short-acting β2 agonists.
dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied and cannot be recommended.
The most frequently recorded concomitant medicinal products for Parkinson's disease in randomized patients were dopamine agonists(64%), and MAO inhibitors 37.
in patients who are unusually responsive to beta2-adrenergic agonists.
peroxisome proliferator-activated receptor gamma(PPAR) agonists, alpha-glucosidase inhibitors, and amylin analogues.